Article
UPDATED: Vivek Ramaswamy's Metavant hits a brick wall, abandoning a lead program for diabetes. An
Rating:
0.0
Views:
108
Likes:
1
Library:
1
Just a few years after Vivek Ramaswamy's epic Alzheimer's fail, another one of his startups is cutting its losses because of a high-risk endeavor — this time on the diabetes front — didn't pan out. Metavant, Ramaswamy's biotech #7, has decided not to advance its lead candidate imeglimin into Phase
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value